Image source: Synergy Pharmaceuticals.

What: After announcing that it will present information on the efficacy and safety of its lead product candidate plecanatide at the Digestive Disease Week 2016 in San Diego, May 21-24, shares of Synergy Pharmaceuticals, (NASDAQ: SGYP) were soaring 13.5% higher at 11:00 a.m. ET today.

So what: The conference will give the company an opportunity to show doctors data from trials evaluating plecanatide for use in patients with chronic idiopathic constipation (CIC). Previously, Synergy Pharmaceuticals reported phase 3 trial results showing that plecanatide effectively addresses CIC and that it does so with a potentially best-in-class low incidence rate of severe diarrhea. 

If its efficacy and safety profile resonate with prescribers, then plecanatide could eventually cut into sales of market leader Linzess, a drug co-marketed by Ironwood Pharmaceuticals (IRWD 2.92%) and Allergan (AGN). On May 9, Ironwood Pharmaceuticals reported that Linzess U.S. net sales increased 44% to $137 million in the first quarter compared to Q1 2015, and that Linzess is on track to exceed $1 billion in net sales by 2020.

Now what: Synergy Pharmaceuticals application for approval was accepted by the Food and Drug Administration earlier this year, and that positions the company to receive approval on plecanatide next January.

The market for constipation drugs is big and plecanatide's safety profile offers an opportunity to win away market share, but investors should remember that Synergy Pharmaceuticals owes nearly $80 million and that spending will increase ahead of commercialization. All that spending means that there's no telling when this company could turn profitable. Also, investors should remember that there's always the risk that the FDA will opt against approving plecanatide, and if that happens, then it would significantly impact the company's share price.

Overall, while the market potential for plecanatide is big enough to make this company intriguing, its balance sheet is a bit of a question mark, and given its unclear path to profitability, I'm focusing on other investment ideas.